NCT06737536

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

A Single- and Multiple-ascending Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of NNC0662-0419 in Participants Living With Overweight or Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	NNC0662-0419	Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
OTHER	Placebo (NNC0662-0419)	Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.

Timeline

• Start date: 2024-12-18
• Primary completion: 2025-07-26
• Completion: 2025-07-26
• First posted: 2024-12-17
• Last updated: 2025-09-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study